- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02426645
Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction
The aim of this study is to investigate associations between early structural cellular injury and microvascular alteration with progression of septic organ dysfunction according to total SOFA-Score (an ICU-scoring system - the Sequential Organ Failure Assessment Score). Patients will be monitored for renal (TIMP-2, IGFBP7), and intestinal biomarkers (plasma i-FABP) in conjunction with kidney and muscle vascular bed microvascular perfusion analysis assessed by contrast-enhanced ultrasonography (CEUS). In parallel, a comprehensive analysis of patients' immunological status will be conducted using an established, on-site immune monitoring panel.
The ultimate goal of this study is an early identification of septic patients developing multiorgan dysfunction which may facilitate a timely novel intervention in the future to improve outcome.
Studieoversikt
Status
Forhold
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
Bavaria
-
Regensburg, Bavaria, Tyskland, 93053
- Department of Surgery, University Hospital Regensburg
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
Patients ≥18 years of age with severe sepsis and fulfill the following criteria at the admission to ICU:
- Peritonitis (abdominal infection) and performed source control (either surgically or interventionally)
- 2 or more criteria for systemic inflammatory response syndrome (temperature >38° or<36°; heart rate >90 beats per minute; respiratory rate >20 breaths per minute or paCO2 <32 mmHg; white blood cell count >12,000/mm3, <4000mm3 or >10% immature forms) and serum lactate level of 4mmol/l and more or refractory hypotension - mean arterial pressure <65mmHg or systolic blood pressure <90mmHg after fluid challenge of 1000ml or more /30min
- Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Written informed consent prior to any study procedures
Exclusion Criteria:
- Pre-existing renal-replacement therapy in the pre-operative course
- Pre-existing shock
- Acute coronary syndrome
- Active hemorrhage
- Trauma
- Known allergy to ultrasound contrast media
- Anemia with hemoglobin concentration < 7g/dl
- Patients not able to give written informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Assessment of early post-operative course of novel cellular injury biomarkers as well as microvascular perfusion in critically ill patients with severe sepsis and to collection any first evidence of the association of these markers with the SOFA-Score
Tidsramme: 60 weeks
|
60 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
28 day mortality
Tidsramme: 60 weeks
|
60 weeks
|
|
90 day mortality
Tidsramme: 60 weeks
|
60 weeks
|
|
Length of ICU stay
Tidsramme: 60 weeks
|
60 weeks
|
|
Length of hospital stay
Tidsramme: 60 weeks
|
60 weeks
|
|
Early post-operative course of microvascular perfusion of the kidney and muscle vasculature bed using CEUS
Tidsramme: 60 weeks
|
60 weeks
|
|
Incidence of acute kidney injury (AKI) within the first 48 hours as based on current Kidney Disease: Improving Global Outcomes (KDIGO) recommendation
Tidsramme: 60 weeks
|
60 weeks
|
|
Incidence of acute kidney injury (AKI) within the first 7 days as based on current Kidney Disease: Improving Global Outcomes (KDIGO) recommendation
Tidsramme: 60 weeks
|
60 weeks
|
|
Need for renal replacement therapy (RRT) after admission to ICU
Tidsramme: 60 weeks
|
60 weeks
|
|
Identification of an "immunological fingerprint" indicating multi-organ dysfunction
Tidsramme: 60 weeks
|
Flow cytometry
|
60 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Marc H Dahlke, Prof. Dr., University Hospital Regensburg
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Mibisep
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sepsis
-
University of Kansas Medical CenterUniversity of KansasRekrutteringSepsis | Septisk sjokk | Sepsis syndrom | Sepsis, alvorlig | Sepsis bakterie | Sepsis bakteriemiForente stater
-
Jip GroenInBiomeRekrutteringMikrobiell kolonisering | Neonatal infeksjon | Neonatal sepsis, tidlig debut | Mikrobiell sykdom | Klinisk sepsis | Kultur negativ neonatal sepsis | Neonatal sepsis, sent debut | Kultur Positiv neonatal sepsisNederland
-
The University of QueenslandRoyal Brisbane and Women's HospitalUkjent
-
Karolinska InstitutetÖrebro University, SwedenFullførtSepsis | Sepsis syndrom | Sepsis, alvorligSverige
-
Ohio State UniversityFullførtSepsis, alvorlig sepsis og septisk sjokkForente stater
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsFullførtSepsis | Septisk sjokk | Alvorlig sepsis | Sepsis syndromStorbritannia
-
Indonesia UniversityFullførtAlvorlig sepsis med septisk sjokk | Alvorlig sepsis uten septisk sjokkIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRekrutteringAlvorlig sepsis | Alvorlig sepsis uten septisk sjokkForente stater
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian... og andre samarbeidspartnereFullførtSepsis | Septisk sjokk | Alvorlig sepsis | Infeksjon | Sepsis syndromForente stater
-
Inverness Medical InnovationsFullførtSepsis | Systemisk inflammatorisk responssyndrom | Alvorlig sepsis | Sepsis syndromForente stater